US Edition
Published • loading... • Updated
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
Eisai presents long-term safety and effectiveness data on lecanemab, including APOE4 homozygous patient outcomes, at the AD/PD 2026 conference in Copenhagen.
- On March 10, 2026, Eisai announced it will present lecanemab findings at AD/PD 2026 from March 17-21, featuring six presentations including three oral talks.
- Following recent regulatory moves, the U.S. Food and Drug Administration approved a subcutaneous maintenance BLA in August 2025 and accepted an sBLA in January 2026 with a PDUFA date of May 24, 2026.
- On March 11, 2026, Eisai said it will present LEADER data on APOE4 homozygous patients and 48‑month Clarity AD open‑label extension results during poster viewing from 7:30 on March 17 to 11:10 on March 19.
- Eisai is sponsoring a symposium that features four global AD experts and states it leads global development and regulatory submissions while co‑promoting lecanemab with Biogen.
- Preclinical biomarker work will be shown, including APPNL‑G‑F/MAPT double knock‑in mouse data linking protofibril reduction to CSF pTau217, as ongoing trials like AHEAD 3‑45 include lecanemab.
Insights by Ground AI
38 Articles
38 Articles
LoudounTimes.com+36 Reposted by 36 other sources
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
TOKYO, March 10, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the…
Coverage Details
Total News Sources38
Leaning Left7Leaning Right3Center15Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 28%
C 60%
12%
Factuality
To view factuality data please Upgrade to Premium
